[go: up one dir, main page]

WO2008145149A1 - Composition antiphlogistique et analgésique pour utilisation topique sur une zone d'un système locomoteur d'un animal - Google Patents

Composition antiphlogistique et analgésique pour utilisation topique sur une zone d'un système locomoteur d'un animal Download PDF

Info

Publication number
WO2008145149A1
WO2008145149A1 PCT/EP2007/004713 EP2007004713W WO2008145149A1 WO 2008145149 A1 WO2008145149 A1 WO 2008145149A1 EP 2007004713 W EP2007004713 W EP 2007004713W WO 2008145149 A1 WO2008145149 A1 WO 2008145149A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogel
composition
antiphlogistic
arnica
active ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/004713
Other languages
English (en)
Inventor
Vincenzo Massimo Lombardo
Alberto Antonio Molinari
Ruggero Ferraiolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2010509684A priority Critical patent/JP2010528065A/ja
Priority to EA200970667A priority patent/EA015702B1/ru
Priority to PCT/EP2007/004713 priority patent/WO2008145149A1/fr
Priority to BRPI0721696-3A priority patent/BRPI0721696A2/pt
Publication of WO2008145149A1 publication Critical patent/WO2008145149A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention refers to an antiphlogistic and analgesic composition for use on the epidermis site where pains are felt from muscles, articulations, tendons and ligaments caused by pathologies, contusions and trauma.
  • the prior art comprises a number of compositions in the form of ointment, cream, spray or foam which are able to assuage the above specified pains and treat their cause in a notable or little extent.
  • the commercial products are cited that are sold under the names of Voltaren ®, Algesal ®, Lasonil ®, Artrosilene ® wherein the active ingredients are, respectively, diclofenac diethyl ammonium, diethyl amine salicylate , ketoprofene, lysine salt ketoprofene whereas there is a number of other products used to the same purposes that employ other active ingredients comprised in the pharmacopeia relevant to said purposes.
  • JP 11 279065 discloses an anti-inflammatory product in the form of topical solution composed by two water soluble anti-inflammatory agents, one of the steroidal type and the other of non-steroidal type, and by hyaluronic acid.
  • the efficacy of the analgesic and anti-inflammatory effect of the known compositions is affected by the fact that such compositions comprise in most cases an active ingredient only which is not well vehiculated into the suffering body region. Consequently, the efficacy of said compositions may be of short time and not so extended in the concerned region.
  • the known compositions may cause undesired effects due to light or notable hyperaesthesia against one or more components and to allergic reactions .
  • the invented compositions obviates the above mentioned limitations and drawbacks and offers advantages that will be described fartheron.
  • the invented composition comprises as active ingredients a salt of hyaluronic acid, an arnica extract and a non steroidal anti-inflammatory agent (FANS - as for instance methyl salicylate, diclofenac, lysine salt ketoprofene) soluble in a gel and, as vehicle of the active ingredients, hydrogel of the type used in medicine for applying ultrasounds and electric transmissions, type of gel which proved to give the compositions the best physical properties and that will be referred to as - hydrogel - in the following.
  • FANS - non steroidal anti-inflammatory agent
  • the hyaluronic acid as anti-inflammatory and chemotactic agent is known for a long time and is generally and successfully used into injectable solutions for treating osteoarthrosis, gonarthrosis, wounds and burns, in the beauty surgery and culture and also as a component for ophthalmic use.
  • the hyarulonic acid is preferably used as sodium hyaluronate, dissolved in just necessary purified water before preparing the composition.
  • Such an efficacy is substantially due to the anti-inflammatory and chemotactic properties as well as to the notable hydrophilia of the hyaluronic acid.
  • the latter makes pores of the basal membrane dilate and, supported by the high vehiculation favoured by the hydrogel, causes itself and the other two antiphlogistic and analgesic components to rapidly penetrate into the suffering region.
  • undesirable effects and allergic reactions of this composition have not been recorded in case of long-term use.
  • any hydrogel-soluble non steroidal anti-inflammatory agent from 2% to 10%, - hydrogel from 70% to 95%,
  • non steroidal anti-inflammatory agents As it is known, there is a number of non steroidal anti-inflammatory agents and the inventors proved that each of them, provided is soluble in hydrogel, may be used in this compositions in a proportion from 2% to 10% in order to provide the composition with the desired efficacy. It has been proved that the most afficacious anti-inflammatory agent in the invented composition is methyl salicylate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne une composition analgésique et antiphlogistique pour une utilisation topique, laquelle composition comprend de 0,01% à 3 % en poids d'acide hyaluronique, de 0,5 % à 7% en poids d'extrait glycolique d'arnica, de 2% à 10% en poids d'un agent anti-inflammatoire non stéroïdien soluble dans l'hydrogel et de 70% à 95% en poids d'hydrogel.
PCT/EP2007/004713 2007-05-28 2007-05-28 Composition antiphlogistique et analgésique pour utilisation topique sur une zone d'un système locomoteur d'un animal Ceased WO2008145149A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2010509684A JP2010528065A (ja) 2007-05-28 2007-05-28 動物運動系の領域における局所使用のための消炎及び鎮痛組成物
EA200970667A EA015702B1 (ru) 2007-05-28 2007-05-28 Противовоспалительная и анальгетическая композиция для местного применения в области опорно-двигательного аппарата животного
PCT/EP2007/004713 WO2008145149A1 (fr) 2007-05-28 2007-05-28 Composition antiphlogistique et analgésique pour utilisation topique sur une zone d'un système locomoteur d'un animal
BRPI0721696-3A BRPI0721696A2 (pt) 2007-05-28 2007-05-28 composição antiflogìstica e analgésica para uso tópico em uma região de um sistema locomotor animal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2007/004713 WO2008145149A1 (fr) 2007-05-28 2007-05-28 Composition antiphlogistique et analgésique pour utilisation topique sur une zone d'un système locomoteur d'un animal

Publications (1)

Publication Number Publication Date
WO2008145149A1 true WO2008145149A1 (fr) 2008-12-04

Family

ID=39471876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/004713 Ceased WO2008145149A1 (fr) 2007-05-28 2007-05-28 Composition antiphlogistique et analgésique pour utilisation topique sur une zone d'un système locomoteur d'un animal

Country Status (4)

Country Link
JP (1) JP2010528065A (fr)
BR (1) BRPI0721696A2 (fr)
EA (1) EA015702B1 (fr)
WO (1) WO2008145149A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119656137A (zh) * 2024-12-20 2025-03-21 沈阳药科大学 一种复方山金车花-双氯芬酸钠凝胶贴膏及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307277A1 (fr) * 1987-09-09 1989-03-15 Marie-Christine Seguin Produit à base de silanol pour les soins des vaisseaux lymphatiques superficiels
WO1991000083A1 (fr) * 1989-06-23 1991-01-10 Revlon, Inc. Preparation pour soins de la peau
EP0695187A1 (fr) * 1993-04-16 1996-02-07 Hyal Pharmaceutical Corporation Compositions pour inhibiter, controller et regresser l'angiogenese, qui contiennent de l'acide hyaluronique et des nsaid
WO2000045796A1 (fr) * 1997-04-22 2000-08-10 Archer Heidi K Compositions analgesiques et antiphlogistiques et enveloppe therapeutique pour administration topique
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
EP1710257A1 (fr) * 2004-01-07 2006-10-11 Seikagaku Corporation Derive d'acide hyaluronique et medicament contenant ce dernier

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0617300B2 (ja) * 1986-09-22 1994-03-09 サンスタ−株式会社 歯周疾患治療用組成物
JP2788340B2 (ja) * 1989-12-21 1998-08-20 株式会社ニッショー 炎症治療剤
CA2061566C (fr) * 1992-02-20 2002-07-09 Rudolf E. Falk Traitement des maladies par l'acide hyaluronique et des ains
CA2154103C (fr) * 1995-07-18 1998-02-24 Samuel Simon Asculai Traitement des maladies, traumatismes ou troubles de la membrane muqueuse, et pour le soulagement de la douleur
JPH11279065A (ja) * 1998-03-25 1999-10-12 Shiseido Co Ltd 局所投与炎症治療剤
JP2005126341A (ja) * 2003-10-22 2005-05-19 Lion Corp 外用消炎鎮痛貼付剤
US20050196450A1 (en) * 2004-03-04 2005-09-08 Elka Touitou Method and composition for burned skin
ITMI20061132A1 (it) * 2006-06-13 2007-12-14 Sinclair Pharmaceuticals Ltd Composizioni topiche antimicrobiche comprendenti lattoferrina, acido ialuronico o suoi sali ed estratti vegetali

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307277A1 (fr) * 1987-09-09 1989-03-15 Marie-Christine Seguin Produit à base de silanol pour les soins des vaisseaux lymphatiques superficiels
WO1991000083A1 (fr) * 1989-06-23 1991-01-10 Revlon, Inc. Preparation pour soins de la peau
EP0695187A1 (fr) * 1993-04-16 1996-02-07 Hyal Pharmaceutical Corporation Compositions pour inhibiter, controller et regresser l'angiogenese, qui contiennent de l'acide hyaluronique et des nsaid
WO2000045796A1 (fr) * 1997-04-22 2000-08-10 Archer Heidi K Compositions analgesiques et antiphlogistiques et enveloppe therapeutique pour administration topique
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
EP1710257A1 (fr) * 2004-01-07 2006-10-11 Seikagaku Corporation Derive d'acide hyaluronique et medicament contenant ce dernier

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119656137A (zh) * 2024-12-20 2025-03-21 沈阳药科大学 一种复方山金车花-双氯芬酸钠凝胶贴膏及其制备方法和应用

Also Published As

Publication number Publication date
EA200970667A1 (ru) 2010-06-30
BRPI0721696A2 (pt) 2011-06-21
JP2010528065A (ja) 2010-08-19
EA015702B1 (ru) 2011-10-31

Similar Documents

Publication Publication Date Title
US5869533A (en) Non-irritating capsaicin formulations and applicators therefor
RU2452475C2 (ru) Средство для лечения ран, ожогов и инфекционно-воспалительных заболеваний кожи, придатков кожи и слизистых оболочек
JP2000143507A (ja) カプサイシン含有外用剤
WO2021236782A1 (fr) Compositions topiques et méthodes de traitement de la douleur
JP6961055B2 (ja) ホメオパシー的療法的方法および組成物
CN109568267B (zh) 一种冰冻镇痛气雾剂及其制备方法
US20080193576A1 (en) Antiphlogistic and analgesic composition for topical use in a region of an animal locomotive system
US20140348873A1 (en) Urea-Silicone Gel for Hyperkeratosis Treatment
EP1818045B1 (fr) Composition antiphlogistic et analgetic pour utilisation topique sur le systeme locomotrice d'une animal
WO2008145149A1 (fr) Composition antiphlogistique et analgésique pour utilisation topique sur une zone d'un système locomoteur d'un animal
RU2408380C1 (ru) Лекарственная композиция для лечения болезней суставов (варианты)
RU2611400C2 (ru) Ранозаживляющий гель для наружного применения
RU2128500C1 (ru) Мазь б.и.варфоломеева для лечения ожогов
CN114948830B (zh) 功能型人体医用清洁湿巾液
CN101259138A (zh) 局部应用于动物运动系统部位的消炎和镇痛组合物
ES2910949T3 (es) Composición que comprende carnitina, colato de sodio, acetato de sodio y opcionalmente plata para su uso en el tratamiento de la psoriasis
CN106880765A (zh) 一种外伤动物模型的构建及促进伤口愈合的方法
US8268364B1 (en) Water based pain relieving composition
RU2603459C1 (ru) Ранозаживляющий гель для наружного применения
RU2682454C1 (ru) Мазь для лечения термических ожогов и способ их лечения
RU2546030C1 (ru) Средство "ихтиосин"
JP6034386B2 (ja) 皮膚に塗布する組成物、およびその使用
CN103463140A (zh) 一种消毒修复液
CN117137819A (zh) 一种草本抑菌儿童洗手液及其制备方法
AU2024275569A1 (en) Topical pharmaceutical skin composition for the delivery of nitric oxide in combination with other topical dermatologic agents

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2331/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200970667

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2010509684

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WD Withdrawal of designations after international publication
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07801407

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 07801407

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: PI0721696

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091127